Recovery from recalcitrant malignant peripheral nerve sheath tumor: A combination of Mohs paste-aided surgical debridement and chemotherapy
Authors:
- 1 November 2019
- journal article
- letter
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (11) , E400-E402
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromasNeuro-Oncology, 2019
- Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overviewHuman Pathology, 2017
- Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1Journal of Clinical Oncology, 2016
- Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumorsNature Genetics, 2014
- PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsNature Genetics, 2014